Advertisement

Topics

ValiRx given US patent boost for its lead therapeutic compound

02:53 EST 11 Jan 2018 | Proactive Investors

VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours.

Original Article: ValiRx given US patent boost for its lead therapeutic compound

NEXT ARTICLE

More From BioPortfolio on "ValiRx given US patent boost for its lead therapeutic compound"

Quick Search
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...